Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PES-Cl is a small molecule inhibitor of the heat shock protein 70 (HSP70) and a potent inhibitor of autophagy. It is a chlorinated analogue of phenylethynesulfonamide (PES) with significantly enhanced potency (approximately 10-fold lower IC50) and improved ability to inhibit autophagy compared to its parent compound. PES-Cl binds specifically to the C-terminal helical 'lid' domain of HSP70, which is abundantly expressed in tumor cells and stabilizes lysosomal membranes. By inhibiting HSP70, PES-Cl disrupts the function of the HSP70/HSC70 co-chaperone system, leading to the degradation of HSP90 client proteins such as HER2, AKT, and CDK4. Additionally, it has been shown to impair the activity of the Anaphase Promoting Complex/Cyclosome (APC/C), inducing G2/M cell cycle arrest. In preclinical studies, PES-Cl demonstrated efficacy against melanoma (including BRAF-inhibitor resistant strains) and B-cell lymphoma with minimal toxicity to normal cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PES-Cl.